Steffen Hartleif1, Hannah Baier1, Matthias Kumpf2, Rupert Handgretinger3, Alfred Königsrainer4, Silvio Nadalin4, Ekkehard Sturm1. 1. Pediatric Gastroenterology and Hepatology (SH, HB, ES), University Hospital Tübingen, Tübingen, Germany. 2. Pediatric Cardiology, Pulmonology and Pediatric Intensive Care Medicine (MK), University Hospital Tübingen, Tübingen, Germany. 3. Pediatric Hematology and Oncology (RH), University Hospital Tübingen, Tübingen, Germany. 4. Department of General, Visceral and Transplant Surgery (AK, SN), University Hospital Tübingen, Tübingen, Germany.
Abstract
OBJECTIVE: Arterial hypertension (AH) is the most common toxic effect of calcineurin inhibitor (CNI)-based immunosuppression in children after liver transplantation (LT). Activation of the renal sodium chloride cotransporter (NCC) by CNIs has been described as a major cause of CNI-induced AH. Thiazides, for example, hydrochlorothiazide (HCTZ), can selectively block the NCC and may ameliorate CNI-induced AH after pediatric LT. METHODS: From 2005 thru 2015 we conducted a retrospective, single-center analysis of blood pressure in 2 pediatric cohorts (each n = 33) with or without HCTZ in their first year after LT. All patients received CNI-based immunosuppression. According to AAP guidelines, AH was defined as stage 1 and stage 2. Cohort 1 received an HCTZ-containing regimen to target the CNI-induced effect on the NCC, leading to AH. Cohort 2 received standard antihypertensive therapy without HCTZ. RESULTS: In children who have undergone LT and been treated with CNI, AH overall was observed less frequently in cohort 1 vs cohort 2 (31% vs 44%; ns). Moreover, severe AH (stage 2) was significantly lower in cohort 1 vs 2 (1% vs 18%; p < 0.001). Multivariate analysis revealed HCTZ as the only significant factor with a protective effect on occurrence of severe stage 2 AH. While monitoring safety and tolerability, mild asymptomatic hypokalemia was the only adverse effect observed more frequently in cohort 1 vs 2 (27% vs 3%; p = 0.013). CONCLUSIONS: Targeting NCC by HCTZ significantly improved control of severe CNI-induced AH and was well tolerated in children who underwent LT. This effect may reduce the risk of long-term end-organ damage and improve quality of life. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org 2022.
OBJECTIVE: Arterial hypertension (AH) is the most common toxic effect of calcineurin inhibitor (CNI)-based immunosuppression in children after liver transplantation (LT). Activation of the renal sodium chloride cotransporter (NCC) by CNIs has been described as a major cause of CNI-induced AH. Thiazides, for example, hydrochlorothiazide (HCTZ), can selectively block the NCC and may ameliorate CNI-induced AH after pediatric LT. METHODS: From 2005 thru 2015 we conducted a retrospective, single-center analysis of blood pressure in 2 pediatric cohorts (each n = 33) with or without HCTZ in their first year after LT. All patients received CNI-based immunosuppression. According to AAP guidelines, AH was defined as stage 1 and stage 2. Cohort 1 received an HCTZ-containing regimen to target the CNI-induced effect on the NCC, leading to AH. Cohort 2 received standard antihypertensive therapy without HCTZ. RESULTS: In children who have undergone LT and been treated with CNI, AH overall was observed less frequently in cohort 1 vs cohort 2 (31% vs 44%; ns). Moreover, severe AH (stage 2) was significantly lower in cohort 1 vs 2 (1% vs 18%; p < 0.001). Multivariate analysis revealed HCTZ as the only significant factor with a protective effect on occurrence of severe stage 2 AH. While monitoring safety and tolerability, mild asymptomatic hypokalemia was the only adverse effect observed more frequently in cohort 1 vs 2 (27% vs 3%; p = 0.013). CONCLUSIONS: Targeting NCC by HCTZ significantly improved control of severe CNI-induced AH and was well tolerated in children who underwent LT. This effect may reduce the risk of long-term end-organ damage and improve quality of life. Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org 2022.
Authors: Nima Memaran; Bianca Borchert-Mörlins; Bernhard M W Schmidt; Rizky I Sugianto; Hannes Wilke; Ricarda Blöte; Ulrich Baumann; Elena Bauer; Anika von Wick; Norman Junge; Christoph Leiskau; Eva D Pfister; Daniela Thurn-Valsassina; Nicolas Richter; Imeke Goldschmidt; Anette Melk Journal: Liver Transpl Date: 2019-03-25 Impact factor: 5.799
Authors: V J Canzanello; S C Textor; S J Taler; D J Wilson; L Schwartz; R H Wiesner; M K Porayko; R A Krom Journal: J Am Soc Nephrol Date: 1995-05 Impact factor: 10.121
Authors: George J Schwartz; Alvaro Muñoz; Michael F Schneider; Robert H Mak; Frederick Kaskel; Bradley A Warady; Susan L Furth Journal: J Am Soc Nephrol Date: 2009-01-21 Impact factor: 10.121
Authors: Ewout J Hoorn; Stephen B Walsh; James A McCormick; Robert Zietse; Robert J Unwin; David H Ellison Journal: J Nephrol Date: 2012 May-Jun Impact factor: 3.902
Authors: Ewout J Hoorn; Stephen B Walsh; James A McCormick; Antje Fürstenberg; Chao-Ling Yang; Tom Roeschel; Alexander Paliege; Alexander J Howie; James Conley; Sebastian Bachmann; Robert J Unwin; David H Ellison Journal: Nat Med Date: 2011-10-02 Impact factor: 53.440